| Literature DB >> 24959555 |
Sabha Bhatti1, Hussein Al-Khalidi2, Kan Hor3, Abdul Hakeem1, Michael Taylor3, Arshed A Quyyumi4, John Oshinski4, Andrew L Pecora5, Dean Kereiakes6, Eugene Chung6, Gianni Pedrizzetti7, Tomasz Miszalski-Jamka8, Wojciech Mazur6.
Abstract
Background. Magnetic resonance imaging (MRI) strain analysis is a sensitive method to assess myocardial function. Our objective was to define the feasibility of MRI circumferential strain (ε cc) analysis in assessing subtle changes in myocardial function following stem cell therapy. Methods and Results. Patients in the Amorcyte Phase I trial were randomly assigned to treatment with either autologous bone-marrow-derived stem cells infused into the infarct-related artery 5 to 11 days following primary PCI or control. MRI studies were obtained at baseline, 3, and 6 months. ε cc was measured in the short axis views at the base, mid and apical slices of the left ventricle (LV) for each patient (13 treatments and 10 controls). Mid-anterior LV ε cc improved between baseline -18.5 ± 8.6 and 3 months -22.6 ± 7.0, P = 0.03. There were no significant changes in ε cc at 3 months and 6 months compared to baseline for other segments. There was excellent intraobserver and interobserver agreement for basal and mid circumferential strain. Conclusion. MRI segmental strain analysis is feasible in assessment of regional myocardial function following cell therapy with excellent intra- and inter-observer variability's. Using this method, a modest interval change in segmental ε cc was detected in treatment group.Entities:
Year: 2012 PMID: 24959555 PMCID: PMC4045523 DOI: 10.5402/2013/371028
Source DB: PubMed Journal: ISRN Radiol ISSN: 2314-4084
Global circumferential strain at base, mid, and apex for cases and controls.
| Strain | Mean | SD | Median |
|
|---|---|---|---|---|
| Treatment | ||||
|
| ||||
| Base | ||||
| Baseline | −18.4 | 14.4 | −22.0 | |
| Month 3 | −24.4 | 4.8 | −24.9 | 0.03 |
| Month 6 | −22.8 | 6.7 | −21.8 | 0.63 |
| Mid | ||||
| Baseline | −18.2 | 12.3 | −21.1 | |
| Month 3 | −20.9 | 5.5 | −21.4 | 0.59 |
| Month 6 | −20.7 | 6.9 | −22.5 | 0.30 |
| Apex | ||||
| Baseline | −16.2 | 6.3 | −15.4 | |
| Month 3 | −16.6 | 6.4 | −15.8 | 0.79 |
| Month 6 | −18.3 | 7.8 | −19.9 | 0.35 |
|
| ||||
| Control | ||||
|
| ||||
| Base | ||||
| Baseline | −21.3 | 6.3 | −20.0 | |
| Month 3 | −21.7 | 4.9 | −21.0 | 0.73 |
| Month 6 | −22.8 | 4.8 | −20.6 | 0.30 |
| Mid | ||||
| Baseline | −20.4 | 6.2 | −19.5 | |
| Month 3 | −19.1 | 6.1 | −18.3 | 0.99 |
| Month 6 | −20.8 | 5.9 | −18.9 | 0.91 |
| Apex | ||||
| Baseline | −20.3 | 9.0 | −17.2 | |
| Month 3 | −21.1 | 8.1 | −20.9 | 0.73 |
| Month 6 | −23.0 | 6.2 | −23.5 | 0.25 |
*Wilcoxon signed-rank test for change from baseline within each group.
Figure 1Segmental strain of mid-anterior (MA) segments at baseline, 3, and 6 months followup in the treatment group. Improvement noted at 3 months (P = 0.03) was no longer present at 6 months (P = 0.34).
Figure 2Late gadolinium enhancement and mid-anterior ε cc for baseline, 3, and 6 months. There was initial improvement at 3 months followup, but deterioration at 6 months, due to left ventricular remodeling.